Delayed-type hypersensitivity response (DTH)

Delayed-type hypersensitivity (DTH) is a cell-mediated immune response characterized by a T-cell-dependent inflammatory reaction to specific antigens (StatPearls, 2023). Classified as Type IV hypersensitivity, it typically manifests 24 to 72 hours after antigen exposure and involves the activation of sensitized CD4+ Th1 or CD8+ T cells (NIH, 2022). Upon re-exposure to an antigen, these T cells release pro-inflammatory cytokines, such as interferon-gamma and tumor necrosis factor, which recruit and activate macrophages to the site of exposure (Janeway's Immunobiology, 2017). While DTH is a protective mechanism against intracellular pathogens like Mycobacterium tuberculosis, it also drives the pathology of allergic contact dermatitis, granulomatous diseases, and organ transplant rejection (NCBI, 2021). Therapeutic intervention typically focuses on suppressing the T-cell and cytokine cascades using corticosteroids or calcineurin inhibitors (PubChem, 2023). As a complex physiological process rather than a single molecule, it is not considered a discrete molecular target for drug discovery, though its individual components (e.g., specific cytokines or receptors) are frequently targeted.

Other names

Type IV hypersensitivityCell-mediated hypersensitivityT-cell mediated hypersensitivityDelayed hypersensitivity

Drugs modulate this response by inhibiting T-cell proliferation, blocking cytokine signaling (such as TNF-alpha or IFN-gamma), or suppressing the recruitment and activation of macrophages at the site of antigen challenge.